A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Inclusion Criteria:

• Have type 2 diabetes

• Have HbA1c ≥7.5% to ≤10.5% at screening

• Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening

• Have had a stable body weight for the three months prior to screening

• On stable treatment dose of one of the following incretins for at least three monthsprior to screening:

• Injectable semaglutide (1 and 2 milligram (mg))

• Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)

Exclusion Criteria:

• Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis orhyperosmolar coma

• Have a prior or planned surgical treatment for obesity

• Have any of the following cardiovascular conditions within three months prior toscreening:

• acute myocardial infarction

• cerebrovascular accident (stroke)

• unstable angina, or

• hospitalization due to congestive heart failure

• Have used insulin to control blood glucose within the past year (short-term useallowed)

• Current use of prohibited oral antihyperglycemic medication (OAM) (including but notlimited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may berandomized if the prohibited OAM treatment was discontinued at least 3 months priorto screening

• If participant has been on stable doses (for at least three months) of up tothree permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/orthiazolidinediones (TZD), they are permitted to participate in the study

• Have taken any medications or alternative remedies for weight loss within threemonths prior to screening